
AtheroMad
@atheromad
Our research group activity is centered around #atherosclerosis, #PCSK9, #extracellularvesicles, #Lipoprotein(A) and #ASCVD biomarkers 🫀
ID: 1519410814595346432
27-04-2022 20:19:15
36 Tweet
79 Followers
84 Following


We demonstrated that #PCSK9 confers inflammatory properties to EVs released by smooth muscle cells #atherosclerosis #ExtracellularVesicles. PCSK9 fuels a feed-forward-inflammatory-loop in atheroma formation pubmed.ncbi.nlm.nih.gov/36361853/ Maria Francesca Greco Massimiliano Ruscica Nicola Ferri


PCSK9 Inhibition and Risk of Diabetes: Should We Worry? It is important to monitor patients, particularly in the earlier phases of treatment, and to identify those more susceptible to develop NOD. Stefano Carugo Lale Tokgozoglu Massimiliano Ruscica pubmed.ncbi.nlm.nih.gov/36383291/


Proud to attend this event...Chiara Macchi is representing our lab Massimiliano Ruscica



#particulatematter exposure and #atherosclerosis. Who are those at higher risk? Do we need mitigation strategies? #EuropeanGreenDeal is an opportunity to make cities healthier through better transport planning and more greenness. sciencedirect.com/science/articl… Massimiliano Ruscica


Excited to be at the EAS Congress 2023, with Chiara presenting our latest data! 🫀EAS Congress Massimiliano Ruscica Pierre Sabouret #EASCongress2023



In 16.8-year follow-up study, #PCSK9 predicts MACE and all-cause mortality in #T2DM patients. cardiab.biomedcentral.com/articles/10.11… Stefano Carugo

Our lab arrived at EVIta- Italian Society for Extracellular Vesicles’s 3rd Symposium in Urbino! 🫧 Massimiliano Ruscica Alessandra Rizzuto






Science is also friendship. Merging different knowledges is the key to success. 🌟 HDL cholesterol efflux capacity and cholesterol loading capacity in long-term fasting - Atherosclerosis atherosclerosis-journal.com/article/S0021-… Robin Mesnage Massimiliano Ruscica
